News & Events - ImCare Biotech

Apr
12
2024
April, 2024: New review paper for Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) published in the journal Diagnostics

A review paper was published in the peer-reviewed journal Diagnostics, titled “Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)”. The paper analyzes the publicly available data on the LC-SPIK biomarker and its performance in detecting early stage liver cancer, […]

ImCare Biotech Team (18530)(0)

Read more

Category

Company
Product
Aug
11
2022
August, 2022: Independent clinical study shows Seravue® has high sensitivity and specificity for the detection of liver cancer in NAFLD and related cirrhotic patients

A recent study has been published by investigators at the University of Turin in the peer-reviewed journal Current Oncology. This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 […]

ImCare Biotech Team (65135)(0)

Read more

Category

Company
Product
Oct
29
2021
October, 2021: ImCare Biotech awarded up to $4M Phase IIB Bridge Award by the National Cancer Institute (NCI/NIH) to support commercialization and approval of Seravue®

ImCare Biotech has been awarded a Phase IIB Bridge Award by the National Cancer Institute (NCI/NIH). This up to $4M over three-year award will be used to help ImCare Biotech pursue commercialization activities and support a pivotal clinical study for FDA clearance of Seravue®, a diagnostic testing product for Hepatocellular Carcinoma (HCC). This follows the […]

ImCare Biotech Team (74774)(0)

Read more

Category

Company
Product
Mar
16
2021
January, 2021: The Centers for Medicare and Medicaid (CMS) announced the MCIT pathway to provide national Medicare coverage for FDA Breakthrough Devices and Diagnostic

The Centers for Medicaid and Medicare (CMS) announced the establishment of the MCIT (Medicare Coverage of Innovative Technology) pathway, which is designed to provide coverage and access to new, innovative medical devices and diagnostics which have received FDA Breakthrough Device Designation to Medicare beneficiaries nationwide. Through this pathway, Breakthrough devices will automatically be eligible for […]

ImCare Biotech Team (75952)(0)

Read more

Category

Company
Product